Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer

Phase I/II Trial of External Irradiation plus Medium-Dose Brachytherapy Given Concurrently to Liposomal Doxorubicin and Cisplatin for Advanced Uterine Cervix Carcinoma

“…This reduced dose intensity may reduce efficacy, as shown in a randomized trial of weekly CDDP doses of 25 mg/m 2 for cervical cancer [48]. However, 30 mg/m 2 of CDDP given weekly during RT had an 88% CR rate and an actuarial 4-year survival rate of 65% in patients with stage IIB-IVA disease, in a nonrandomized study [36].…”

Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix

“…Of note, this trial showed a preferential survival benefit for stage IB-IIB disease treated with concurrent cisplatinum and 5-fluorouracil, while there was no survival or disease-free survival demonstrated for stages III-IVA. There are two other small, randomized trials of locally advanced cervix cancer testing cisplatinum-based concurrent chemotherapy that do not show a benefit of chemotherapy [84,85].…”

Use of Concept of Chemotherapy-Equivalent Biologically Effective Dose to Provide Quantitative Evaluation of Contribution of Chemotherapy to Local Tumor Control in Chemoradiotherapy Cervical Cancer Trials

“…Randomized controlled trials have shown that RT combined with platinum-based chemotherapy can increase the rate of local response and survival (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13), although others have failed to demonstrate such a difference (Leborgne F, 2000, unpublished data; referred to Green et al [12]) (14)(15)(16)(17)(18).…”